Evidence map›Paper›PMID 26315836›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015

18F-Labeled Single-Stranded DNA Aptamer for PET Imaging of Protein Tyrosine Kinase-7 Expression.

Orit Jacobson, Ido D Weiss, Lu Wang, Zhe Wang, Xiangyu Yang, Andrew Dewhurst, Ying Ma, Guizhi Zhu, Gang Niu, Dale O Kiesewetter and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Article
  3. SyntheticRSC medicinal chemistry · 2024
    Review
  4. In Vivo Evaluation ofPharmaceutics · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Radiochemical Synthesis of 4-[Molecules (Basel, Switzerland) · 2022
    Article
  10. Therapeutic Potential of Aptamer-Protein Interactions.ACS pharmacology & translational science · 2022
    Review
  11. Review
  12. Article
  13. Advances in aptamer-based nuclear imaging.European journal of nuclear medicine and molecular imaging · 2022
    Review
  14. Review
  15. Radiolabeling of functional oligonucleotides for molecular imaging.Frontiers in bioengineering and biotechnology · 2022
    Review
  16. Aptamer Applications in Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  17. Article
  18. Review
  19. FacileNature protocols · 2019
    Article
  20. PET imaging of EGFR expression using anEuropean journal of nuclear medicine and molecular imaging · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Orit Jacobson *Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Ido D Weiss *Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases; National Institutes of Health, Bethesda, MD, USA.
Lu WangDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, USA.
Zhe WangLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Xiangyu YangLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Andrew DewhurstLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Ying MaLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Guizhi ZhuLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Gang NiuLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Dale O KiesewetterLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Neil VasdevDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, USA.
Steven H LiangDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, USA.
Xiaoyuan ChenLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Massachusetts General Hospital · US

Funding

Laboratory of Molecular Imaging and NanomedicineZIAEB000073 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI CHEN, XIAOYUAN · 2010 to 2020
$32.8M
New PET tracers for neuroimaging of FAAH in endocannabinoid signalingK01DA038000 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2014 to 2018
$927k
Intramural NIH HHSNIDA NIH HHS K01 DA038000
6 · The paper itself

Abstract

unlabelledProtein tyrosine kinase-7 (PTK7), a member of receptor tyrosine kinase superfamily initially identified as colon carcinoma kinase-4, is highly expressed in various human malignancies. Its expression was found to correlate with aggressive biologic behaviors such as increased cell proliferation, invasiveness, and migration. Despite the importance and unmet need of imaging PTK7 in vivo, there is currently no clinically relevant method to visualize tumoral PTK7 expression noninvasively such as PET or SPECT. This study aimed to develop a specific, selective, and high-affinity PET radioligand based on single-stranded DNA aptamer to address this challenge.

methodsSgc8, a 41-oligonucleotide that targets to PTK7, was labeled with (18)F using a 2-step radiochemical synthesis, which featured a direct 1-step radiofluorination on the distinctive spirocyclic hypervalent iodine(III) precursor to give (18)F-fluorobenzyl azide followed by copper-mediated click conjugation with Sgc8-alkyne. (18)F-Sgc8 was evaluated in vitro and in vivo in 2 cell lines, HCT116 and U87MG, which express high and low amounts of PTK7, respectively.

resultsSgc8 was labeled efficiently with (18)F in an isolated radiochemical yield of 62% ± 2%, non-decay-corrected based on (18)F-fluorobenzyl azide. (18)F-Tr-Sgc8 was found to possess high-affinity binding to both cell lines, with binding affinity values of 2.7 ± 0.6 nM for HCT116 and 16.9 ± 2.1 nM for U87MG. In vivo PET imaging clearly visualized PTK7 expression in HCT116 xenografted mice, with tumor uptake of 0.76 ± 0.09 percentage injected dose per gram (%ID/g) at 30 min after injection for the subcutaneous tumor model and greater than 1.5 %ID/g for the liver metastasis model. U87MG xenograft tumors had much lower tracer accumulation (0.13 ± 0.06 %ID/g at 30 min after injection), which was consistent with the lower expression of PTK7 in this tumor model. The labeled aptamer was rapidly cleared from the blood through the kidneys and bladder to give high tumor-to-blood and tumor-to-muscle ratios of 7.29 ± 1.51 and 10.25 ± 2.08, respectively.

conclusionThe (18)F-radiolabeling methodology shown here is a robust procedure for labeling aptamers and similar chemical moieties and can be applied to many different targets. Quantification of PTK7 using (18)F-Tr-Sgc8 may be suitable for clinical translation and might help in the future to select and monitor appropriate therapies.

Indexed as

AnimalsAptamers, NucleotideCell Adhesion MoleculesCell Line, TumorDNA, Single-StrandedFluorine RadioisotopesGene Expression Regulation, EnzymologicHumansIsotope LabelingMiceNeoplasms, ExperimentalPositron-Emission TomographyRadiopharmaceuticalsReceptor Protein-Tyrosine KinasesTissue DistributionTomography, Emission-Computed, Single-Photon18F-Tr-Sgc8Aptamers, NucleotideCell Adhesion MoleculesDNA, Single-StrandedFluorine RadioisotopesPTK7 protein, humanRadiopharmaceuticalsReceptor Protein-Tyrosine Kinases18Fclick chemistryPET imagingPTK7ssDNA aptamer

Identifiers

PMID26315836
PMCPMC4918919
OpenAlexW1959247563

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.